What Will Happen to Aradigm Corporation (ARDM) Next? The Stock Just Increased A Lot

December 12, 2017 - By Adrian Erickson

Investors sentiment increased to 1.5 in 2017 Q2. Its up 0.10, from 1.4 in 2017Q1. It increased, as 2 investors sold Aradigm Corporation shares while 2 reduced holdings. 5 funds opened positions while 1 raised stakes. 5.08 million shares or 0.89% less from 5.12 million shares in 2017Q1 were reported.
Northern Tru reported 10,414 shares. Creative Planning reported 6 shares or 0% of all its holdings. Vanguard Grp Inc owns 124,043 shares. Great Point Prtn Ltd Com owns 637,279 shares or 0.15% of their US portfolio. Tower Cap Ltd Limited Liability Company (Trc) owns 474 shares for 0% of their portfolio. Deutsche Bankshares Ag has invested 0% in Aradigm Corporation (NASDAQ:ARDM). Morgan Stanley holds 0% of its portfolio in Aradigm Corporation (NASDAQ:ARDM) for 15,010 shares. 11,202 are held by Renaissance Techs Ltd Company. Blackrock reported 3,707 shares. Focused Wealth accumulated 2 shares or 0% of the stock. Fmr Llc accumulated 168,740 shares. Evercore Wealth Ltd, a New York-based fund reported 2 shares. New York-based First Eagle Invest Management Limited Com has invested 0.01% in Aradigm Corporation (NASDAQ:ARDM).

The stock of Aradigm Corporation (NASDAQ:ARDM) is a huge mover today! The stock increased 5.87% or $0.27 during the last trading session, reaching $4.95. About 152,221 shares traded. Aradigm Corporation (NASDAQ:ARDM) has declined 71.40% since December 12, 2016 and is downtrending. It has underperformed by 88.10% the S&P500.
The move comes after 6 months positive chart setup for the $71.85M company. It was reported on Dec, 12 by Barchart.com. We have $5.30 PT which if reached, will make NASDAQ:ARDM worth $5.03 million more.

More notable recent Aradigm Corporation (NASDAQ:ARDM) news were published by: Businesswire.com which released: “Aradigm Announces FDA Advisory Committee Meeting for Linhaliq” on December 01, 2017, also Businesswire.com with their article: “Aradigm to Host Key Opinion Leader Meeting and Webcast on November 9 in New …” published on November 07, 2017, Businesswire.com published: “Aradigm Announces First Quarter 2017 Financial Results” on May 15, 2017. More interesting news about Aradigm Corporation (NASDAQ:ARDM) were released by: Seekingalpha.com and their article: “Aradigm: Hidden Binary Event Or Russian Roulette (With The FDA Spinning The …” published on September 22, 2017 as well as Streetinsider.com‘s news article titled: “Aradigm Corp. (ARDM) Announces Mixed Results from Two Pulmaquin Phase 3s in …” with publication date: December 01, 2016.

Aradigm Corporation, a specialty pharmaceutical company, focuses on the development and commercialization of drugs for the prevention and treatment of severe respiratory diseases. The company has market cap of $71.85 million. The companyÂ’s lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin (ARD-3100) that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis and cystic fibrosis. It currently has negative earnings. It is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis and non-tuberculous mycobacteria, as well as the prevention and treatment of high threat and bioterrorism infections, such as inhaled tularemia, pneumonic plague, melioidosis, Q fever, and inhaled anthrax.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.